Vivoo FlowPad: At-Home Hormone Test via Menstrual Pad

At CES 2026, health technology startup Vivoo introduced the FlowPad, a novel product designed to merge menstrual hygiene with at-home health diagnostics. The device is a menstrual pad that doubles as a diagnostic tool, specifically measuring follicle-stimulating hormone (FSH) levels. This innovation targets the growing market for accessible, non-invasive health monitoring.

The FlowPad is priced at a consumer-friendly point of roughly $4 to $5. It offers flexibility in how users receive their health data. Individuals can interpret results directly from the pad, or they can utilize the Vivoo app to take a photograph of the pad for deeper analysis and insights. This launch marks a significant evolution for the company, which began with vaginal pH tracking liners.

The Consumer Electronics Show (CES) 2026 served as the backdrop for Vivoo's latest announcement. The startup is entering a competitive field where wellness technology companies are increasingly looking to bodily fluids for health data. While blood, urine, sweat, and saliva have been the primary focus for many, Vivoo is shifting attention to menstrual blood.

The FlowPad represents a dual-purpose product. It maintains the utility of a standard menstrual pad while integrating diagnostic capabilities. By targeting follicle-stimulating hormone, the device addresses specific health monitoring needs that are traditionally accessed through clinical visits or complex testing kits.

The core functionality of the FlowPad relies on its ability to analyze menstrual blood for FSH levels. The process is designed to be straightforward for the user. Once the pad is used, the testing mechanism activates, providing a reading that indicates the user's hormone levels.

To ensure accessibility, Vivoo has implemented two distinct methods for result retrieval:

• Direct Viewing: Users can read the results directly from the indicators on the pad.
• App Integration: Users can take a picture of the pad using the Vivoo app, which then provides additional insights and data tracking.

This approach allows for both immediate feedback and detailed, long-term tracking of hormone fluctuations.

The development of the FlowPad is the result of Vivoo's ongoing research into women's health technology. Miray Tayfun, the Vivoo CEO and cofounder, provided context on the company's journey. The startup did not begin with hormone testing but rather with pH monitoring.

Tayfun explained the progression of the company's technology: "We started as a vaginal pH tracking liner for your panties that would change color with vaginal discharge." This foundational technology has now evolved into the more complex FSH testing capability found in the FlowPad. This shift highlights the company's commitment to expanding the scope of at-home diagnostic tools available to consumers.

The introduction of the FlowPad comes amidst a broader trend in the health tech industry. Companies are actively seeking ways to make health monitoring more convenient and less invasive. By utilizing menstrual blood—a fluid that is regularly expelled and easily accessible—Vivoo is tapping into an unmet need for continuous or regular monitoring without the discomfort of needles or invasive procedures.

While the product was announced at CES 2026, the focus remains on the specifications and capabilities of the device itself. With a price point estimated between $4 and $5, the FlowPad is positioned as an affordable alternative to traditional testing methods, potentially making hormone monitoring a routine part of menstrual care for many users.